Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb Company (CH:BMY)
:BMY
BMY Stock Chart & Stats
Day’s Range― - ―
52-Week RangeCHF54.24 - CHF54.24
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
CHF84.66B
Enterprise ValueCHF163.94B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)19.8
Beta0.00
Next Earnings
Apr 24, 2025EPS Estimate
1.24Last Dividend Ex-Date
Apr 04, 2025Dividend Yield4.82%
Share Statistics
EPS (TTM)1.37
Shares Outstanding2,035,080,800
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.78
Enterprise Value/Ebitda10.13
Forecast
1Y Price Target
CHF46.12Price Target Upside-14.98% Downside
Rating ConsensusHold
Number of Analyst Covering21
---
Bulls Say, Bears Say
Bulls Say
Business DevelopmentBMY is prioritizing external business development, which could add new growth drivers.
EarningsQ1 revenues beat expectations, driven mostly by established brands like Eliquis, Opdivo, and Revlimid.
Product LaunchesThe focus on Cobenfy's strong launch and upcoming key clinical readouts are expected to be significant.
Bears Say
Clinical TrialsThe failures of two clinical trials—Camzyos in nHCM and Cobenfy in adjunctive schizophrenia—have also contributed to the decline in BMY shares.
Generic PressuresSeveral years of down earnings are expected due to generic pressures, creating a challenging intermediate-term growth profile.
Sector ChallengesBMY shares have pulled back significantly due to recent sector-wide issues including tariffs, FDA challenges, and drug pricing risks.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.05% Insiders
22.04%
Mutual Funds
0.44% Other Institutional Investors
53.21% Public Companies and
Individual Investors
BMY FAQ
What was Bristol-Myers Squibb Company’s price range in the past 12 months?
Bristol-Myers Squibb Company lowest stock price was CHF54.24 and its highest was CHF54.24 in the past 12 months.
What is Bristol-Myers Squibb Company’s market cap?
Bristol-Myers Squibb Company’s market cap is CHF84.66B.
When is Bristol-Myers Squibb Company’s upcoming earnings report date?
Bristol-Myers Squibb Company’s upcoming earnings report date is Apr 24, 2025 which is 11 days ago.
How were Bristol-Myers Squibb Company’s earnings last quarter?
Bristol-Myers Squibb Company released its earnings results on Apr 24, 2025. The company reported CHF1.494 earnings per share for the quarter, beating the consensus estimate of CHF1.241 by CHF0.253.
Is Bristol-Myers Squibb Company overvalued?
According to Wall Street analysts Bristol-Myers Squibb Company’s price is currently Overvalued.
Does Bristol-Myers Squibb Company pay dividends?
Bristol-Myers Squibb Company pays a Quarterly dividend of CHF2.007 which represents an annual dividend yield of 4.82%. See more information on Bristol-Myers Squibb Company dividends here
What is Bristol-Myers Squibb Company’s EPS estimate?
Bristol-Myers Squibb Company’s EPS estimate is 1.24.
How many shares outstanding does Bristol-Myers Squibb Company have?
Bristol-Myers Squibb Company has 2,035,080,800 shares outstanding.
What happened to Bristol-Myers Squibb Company’s price movement after its last earnings report?
Bristol-Myers Squibb Company reported an EPS of CHF1.494 in its last earnings report, beating expectations of CHF1.241. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb Company?
Currently, no hedge funds are holding shares in CH:BMY
---
Bristol-Myers Squibb Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF46.12 (-14.98% Downside)
CHF46.12 (-14.98% Downside)
Blogger Sentiment
Bullish
CH:BMY Sentiment 70%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $412.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.41%
12-Months-Change
Fundamentals
Return on Equity
31.99%
Trailing 12-Months
Asset Growth
-6.67%
Trailing 12-Months
Company Description
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
---
BMY Company Deck
---
BMY Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call showed strong financial performance and successful product launches, which were slightly overshadowed by disappointing clinical trial results and challenges related to the regulatory environment and Medicare Part D redesign.Read More>---
BMY Revenue Breakdown
70.61% U.S.
27.33% International
2.06% Other
---
BMY Stock 12 Month Forecast
Average Price Target
CHF46.12
▼(-14.98% Downside)
Technical Analysis
---